170 related articles for article (PubMed ID: 15285301)
1. Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
Piura B; Rabinovich A
Eur J Gynaecol Oncol; 2004; 25(4):449-52. PubMed ID: 15285301
[TBL] [Abstract][Full Text] [Related]
2. Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Suprasert P; Cheewakriangkrai C; Manopunya M
Asian Pac J Cancer Prev; 2012; 13(2):517-20. PubMed ID: 22524817
[TBL] [Abstract][Full Text] [Related]
3. Weekly single-agent carboplatin in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
Piura B; Meirovitz M
Eur J Gynaecol Oncol; 2005; 26(4):386-90. PubMed ID: 16122184
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
Silver DF; Piver MS
Am J Clin Oncol; 1999 Oct; 22(5):450-2. PubMed ID: 10521056
[TBL] [Abstract][Full Text] [Related]
5. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
[TBL] [Abstract][Full Text] [Related]
6. Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Goff BA; Thompson T; Greer BE; Jacobs A; Storer B;
Am J Obstet Gynecol; 2003 Jun; 188(6):1556-62; discussion 1562-4. PubMed ID: 12824993
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
8. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
Piura B; Rabinovich A
Int J Gynecol Cancer; 2005; 15(4):612-7. PubMed ID: 16014114
[TBL] [Abstract][Full Text] [Related]
9. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
[TBL] [Abstract][Full Text] [Related]
10. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
Tewari D; Monk BJ; Hunter M; Falkner CA; Burger RA
Invest New Drugs; 2004 Nov; 22(4):475-80. PubMed ID: 15292718
[TBL] [Abstract][Full Text] [Related]
12. Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Goff BA; Holmberg LA; Veljovich D; Kurland BF;
Gynecol Oncol; 2008 Aug; 110(2):146-51. PubMed ID: 18538834
[TBL] [Abstract][Full Text] [Related]
13. The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Safra T; Asna N; Veizman A; Shpigel S; Matcejevsky D; Inbar M; Grisaru D
Anticancer Drugs; 2014 Mar; 25(3):340-5. PubMed ID: 24185383
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Griffiths RW; Zee YK; Evans S; Mitchell CL; Kumaran GC; Welch RS; Jayson GC; Clamp AR; Hasan J
Int J Gynecol Cancer; 2011 Jan; 21(1):58-65. PubMed ID: 21178570
[TBL] [Abstract][Full Text] [Related]
15. Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer.
Cohen S; Schwartz M; Dottino P; Beddoe AM
J Ovarian Res; 2019 Apr; 12(1):36. PubMed ID: 31027500
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Seliger G; Mueller LP; Kegel T; Kantelhardt EJ; Grothey A; Groe R; Strauss HG; Koelbl H; Thomssen C; Schmoll HJ
Int J Gynecol Cancer; 2009 Nov; 19(8):1446-53. PubMed ID: 20009905
[TBL] [Abstract][Full Text] [Related]
17. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
18. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
19. Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Liu FS; Ho ES; Hung MJ; Hwang SF; Lu CH; Ke YM
Gynecol Oncol; 2004 Aug; 94(2):393-7. PubMed ID: 15297178
[TBL] [Abstract][Full Text] [Related]
20. Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Yoshino K; Hiramatsu K; Enomoto T; Fujita M; Ueda Y; Kimura T; Kobayashi E; Kiyohara Y; Tsutsui T; Kimura T
Anticancer Res; 2012 Sep; 32(9):4029-33. PubMed ID: 22993355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
